Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 25 April 2024 and 26 April 2024 regarding the issuance of a total of 9,541,984 shares (the "Offer Shares") by the Company's extraordinary general meeting and the board of directors pursuant to a board authorization relating to a partially guaranteed share offering (the "Offering").
The share capital increases relating to the Offering have today been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 4,961,030.30, divided into 49,610,303 shares, each with a par value of NOK 0.10.
The Offer Shares are expected to be registered in the Norwegian Central Securities Depository (VPS) today, or tomorrow, 14 May 2024.
Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth Oslo.
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.